Cochlear Ltd (ASX: COH) shares showed further signs of stabilising on Tuesday.
The hearing implant giant climbed 1.6% to $123.20, extending its gain over the past month to 16%.
That's an impressive rebound after one of the ASX's most dramatic share price collapses this year.
But let's keep things in perspective. Despite the recent recovery, Cochlear shares are still down around 53% in 2026 and have shed almost 59% over the past 12 months.
So, is this the start of a genuine comeback, or merely a relief rally?
Image source: Getty Images
What went wrong?
April was one of the darkest months in Cochlear's history.
The healthcare company shocked investors when it revealed demand for hearing implants across developed markets had weakened more than expected. At the same time, conflict in the Middle East disrupted shipments and led to order cancellations.
Management responded by dramatically lowering its profit expectations. Instead of forecasting underlying net profit of between $435 million and $460 million for FY26, Cochlear slashed guidance to just $290 million to $330 million.
Investors didn't hang around to hear the rest. Cochlear shares plunged more than 40% in a single session as the market questioned whether one of the ASX's most reliable growth stories had hit a wall.
Since then, investors have been asking one question: is this a temporary stumble or something more serious?
Why the investment case remains intact
Despite the earnings shock, Cochlear's competitive position hasn't fundamentally changed.
The company still commands roughly half of the global cochlear implant market, making it the clear industry leader. That position has been built through decades of product innovation, clinical research, and strong relationships with hospitals and surgeons around the world.
Those competitive advantages are exceptionally difficult for new entrants to replicate.
The long-term growth opportunity for Cochlear shares also remains compelling.
More than six million people across developed markets are estimated to be eligible for cochlear implants, yet only around 3% have received one. That leaves a substantial untapped market as diagnosis rates improve, awareness grows, and technology continues to advance.
In other words, the company's long-term runway may be just as attractive today as it was before April's profit warning.
What do the experts think?
Broker sentiment suggests caution rather than outright pessimism.
According to TradingView data, hold remains the dominant recommendation among analysts.
The average 12-month price target sits at $127.64, implying only around 4% upside from current levels. That suggests many brokers believe the recent rebound of Cochlear shares has already captured much of the near-term recovery.
Not everyone agrees. Six of the 18 analysts covering Cochlear have either a buy or strong buy recommendation, with the most optimistic forecasting the shares could rise another 38% over the next year.
On the other hand, two analysts recommend selling. The lowest target price stands at $100, implying downside of roughly 19%.
